药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
Testosterone Cypionate 200 mg/mL (in Grapeseed Oil), Packaged in a) 10 mL Multi-Dose vial, NDC 73198-0054-10; b) 5 mL Multi-Dose vial, NDC 73198-0054-05, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835.
编号:D-0823-2022登记状态:公开召回企业 / 申办者:Olympia Compounding Pharmacy dba Olympia Pharmacy
登记的停止原因(原文):FDA 召回:CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
Testosterone Cypionate 200 mg/mL, (in Sesame Oil), Packaged in a) 10 mL Multi-Dose vial, NDC 73198-0055-10; b) 5 mL Multi-Dose vial, NDC 73198-0055-05, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835.
编号:D-0824-2022登记状态:公开召回企业 / 申办者:Olympia Compounding Pharmacy dba Olympia Pharmacy
登记的停止原因(原文):FDA 召回:CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
Ultratest, Testosterone Cypionate 160 mg/mL, Testosterone Propionate 40 mg/mL, 10 mL Multi-Dose vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0058-10.
编号:D-0825-2022登记状态:公开召回企业 / 申办者:Olympia Compounding Pharmacy dba Olympia Pharmacy
登记的停止原因(原文):FDA 召回:CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
Hydroxocobalamin B12, 1 mg/mL, 30 mL Multi-Dose vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0080-30.
编号:D-0826-2022登记状态:公开召回企业 / 申办者:Olympia Compounding Pharmacy dba Olympia Pharmacy
登记的停止原因(原文):FDA 召回:CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
Sincalide. Lyophilized powder for reconstitution. 5 mcg per Multi-Dose vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0082-00.
编号:D-0827-2022登记状态:公开召回企业 / 申办者:Olympia Compounding Pharmacy dba Olympia Pharmacy
登记的停止原因(原文):FDA 召回:CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
NAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0083-00
编号:D-0828-2022登记状态:公开召回企业 / 申办者:Olympia Compounding Pharmacy dba Olympia Pharmacy
登记的停止原因(原文):FDA 召回:Failed Reconstitution time;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-05-04
Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80
编号:D-0845-2022登记状态:公开召回企业 / 申办者:Mylan Pharmaceuticals Inc
登记的停止原因(原文):FDA 召回:Labeling: Missing label on the vial;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-04-27
Diclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid, 150 ml bottle, Rx Only, Mfg: Sola Pharmaceutical, Preferred Pharmaceuticals, Inc., The Physicians Solutions, NDC 68788-7918-01
编号:D-0773-2022登记状态:公开召回企业 / 申办者:Preferred Pharmaceuticals, Inc.
登记的停止原因(原文):FDA 召回:CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.;安全性相关:未知
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-04-27
Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60
编号:D-0774-2022登记状态:公开召回企业 / 申办者:Mylan Pharmaceuticals Inc
登记的停止原因(原文):FDA 召回:Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.;安全性相关:是
查看官方原始记录 ↗药品公告与召回美国 FDA 药品召回报告来源日期:2022-04-27
ARA-290 (Cibinetide Acetate) 6 mg/mL (4 mL) Injection, 4 mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 USA
编号:D-0775-2022登记状态:公开召回企业 / 申办者:North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
登记的停止原因(原文):FDA 召回:Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.;安全性相关:是
查看官方原始记录 ↗